Robert A. Nichols to Alzheimer Disease
This is a "connection" page, showing publications Robert A. Nichols has written about Alzheimer Disease.
Connection Strength
1.193
-
Lantz MJ, Roberts AM, Delgado DD, Nichols RA. The neuroprotective N-terminal amyloid-? core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer's disease pathology models. J Neuroinflammation. 2023 May 27; 20(1):129.
Score: 0.556
-
Arora K, Alfulaij N, Higa JK, Panee J, Nichols RA. Impact of sustained exposure to ?-amyloid on calcium homeostasis and neuronal integrity in model nerve cell system expressing a4?2 nicotinic acetylcholine receptors. J Biol Chem. 2013 Apr 19; 288(16):11175-90.
Score: 0.274
-
Tan X, Liang Z, Li Y, Zhi Y, Yi L, Bai S, Forest KH, Nichols RA, Dong Y, Li QX. Isoorientin, a GSK-3? inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice. Behav Brain Res. 2021 02 01; 398:112968.
Score: 0.116
-
Arora K, Belcaid M, Lantz MJ, Taketa R, Nichols RA. Transcriptome Profile of Nicotinic Receptor-Linked Sensitization of Beta Amyloid Neurotoxicity. Sci Rep. 2020 03 30; 10(1):5696.
Score: 0.112
-
Forest KH, Nichols RA. Assessing Neuroprotective Agents for A?-Induced Neurotoxicity. Trends Mol Med. 2019 08; 25(8):685-695.
Score: 0.106
-
Roberts JP, Stokoe SA, Sathler MF, Nichols RA, Kim S. Selective coactivation of a7- and a4?2-nicotinic acetylcholine receptors reverses beta-amyloid-induced synaptic dysfunction. J Biol Chem. 2021 Jan-Jun; 296:100402.
Score: 0.030